EML-panel-video-article-header-EN

Watch it now: WFH expert panel video on the WHO EML and EMLc update

The global bleeding disorders community has reached an important milestone: in 2025, the World Health Organization has updated both its Essential Medicines List (EML) and Essential Medicines List for Children to align with modern international guidelines for hemophilia and von Willebrand disease. Led by the World Federation of Hemophilia (WFH), this successful revision reflects two years of coordinated advocacy, scientific collaboration, and direct engagement with the WHO. The WFH experts’ panel discussion—where stakeholders reflected on the importance of these milestone changes held in November—is now available on the WFH eLearning Platform.

Also available in: Français Español

The revisions introduced in the recently published 24th EML and 10th EMLc will help to increase equitable access to safer and more effective therapies for people with bleeding disorders worldwide. The critical changes include adding emicizumab and recombinant FVIII and FIX concentrates to the core list, and elevating plasma-derived FVIII and FIX concentrates as well as desmopressin from the complementary to the core list. Also, pathogen-reduced and non-pathogen reduced cryoprecipitate have been removed as treatment options for hemophilia and VWD, while Factor IX Complex (PCC) was deleted from the list as a therapeutic alternative to FIX concentrates. Read the full article on all the changes, “WFH mobilizes global community to achieve milestone revisions to WHO EML” by clicking here.

To watch the panel discussion, click on the video below or click here to see it on the WFH eLearning Platform. The panel chaired by David Page, Consultant, Safety and Supply of Coagulation Products, Canadian Hemophilia Society and WFH Coagulation Product Safety, Supply and Access (CPSSA) Committee Member, includes the following speakers (in order of their seating in the video, left to right): Alain Baumann, CEO, WFH; Glenn Pierce, MD, PhD, WFH Vice President, Medical; Salome Mekhuzla, Director, Global Development, WFH; Radek Kaczmarek, Chair of the Coagulation Product Safety, Supply and Access (CPSSA) Committee, WFH; Mark W. Skinner, Board Member, WFH USA; Maria Elisa Mancuso, MD; Brian O’Mahony, Chief Executive, Irish Haemophilia Society; and Cesar Garrido, President, WFH.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.